Literature DB >> 850145

Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.

P Consroe, A Wolkin.   

Abstract

A comparison of the anticonvulsant and neurotoxic effects of cannabidiol (CBD), delta 9tetrahydrocannabinol, cannabinol and antiepileptic drugs (phenytoin, phenobarbital, carbamazepine, chlordiazepoxide, clonazepam, ethosuximide and trimethadione) was made in rats. Median effective potencies (ED 50 values) for maximal electroshock, audiogenic seizures and TD50 values for a rotor rod neurotoxicity test were calculated. Additionally, the interactive effects of CBD and the antiepileptic drugs against maximal electroshock and audiogenic seizures were studied. Each drug was given orally at peak effect time. CBD was an effective and relatively potent anticonvulsant in both maximal electroshock and audiogenic seizure tests. The anticonvulsant potency of phenytoin was significantly increased when combined with phenobarbital, CBD and phenobarbital plus CBD. Additionally, CBD reliably reduced the anticonvulsant potencies of chlordiazepoxide, clonazepam, trimethadione and ethosuximide. These data indicate that CBD is an effective anticonvulsant with a specificity more comparable to drugs clinically effective in major than minor seizures. Furthermore, it appears that CBD enhances the anticonvulsant effects of the former and reduces the effects of the latter types of antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 850145

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  36 in total

1.  Marijuana use and the risk of new onset seizures.

Authors:  J C Brust; S K Ng; A W Hauser; M Susser
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

Review 2.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

3.  Interactions between cannabidiol and Δ9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Ivan K Low; Iain S McGregor; Jonathon C Arnold
Journal:  Br J Pharmacol       Date:  2020-07-27       Impact factor: 8.739

Review 4.  Marijuana Use in Epilepsy: The Myth and the Reality.

Authors:  Kamil Detyniecki; Lawrence Hirsch
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

5.  Intercannabinoid and cannabinoid-ethanol interactions on human performance.

Authors:  K D Bird; T Boleyn; G B Chesher; D M Jackson; G A Starmer; R K Teo
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

6.  The genetically epilepsy-prone rat (GEPR).

Authors:  P C Jobe; P K Mishra; L E Adams-Curtis; V U Deoskar; K H Ko; R A Browning; J W Dailey
Journal:  Ital J Neurol Sci       Date:  1995 Feb-Mar

7.  Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Authors:  Nicholas A Jones; Andrew J Hill; Imogen Smith; Sarah A Bevan; Claire M Williams; Benjamin J Whalley; Gary J Stephens
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

Review 8.  Pediatric Concerns Due to Expanded Cannabis Use: Unintended Consequences of Legalization.

Authors:  George Sam Wang
Journal:  J Med Toxicol       Date:  2016-05-02

9.  Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure.

Authors:  Mahshid Hosseinzadeh; Sara Nikseresht; Fariba Khodagholi; Nima Naderi; Nader Maghsoudi
Journal:  J Mol Neurosci       Date:  2016-01-06       Impact factor: 3.444

10.  Enantiomeric cannabinoids: stereospecificity of psychotropic activity.

Authors:  R Mechoulam; J J Feigenbaum; N Lander; M Segal; T U Järbe; A J Hiltunen; P Consroe
Journal:  Experientia       Date:  1988-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.